NO20051561L - Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. - Google Patents

Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.

Info

Publication number
NO20051561L
NO20051561L NO20051561A NO20051561A NO20051561L NO 20051561 L NO20051561 L NO 20051561L NO 20051561 A NO20051561 A NO 20051561A NO 20051561 A NO20051561 A NO 20051561A NO 20051561 L NO20051561 L NO 20051561L
Authority
NO
Norway
Prior art keywords
nucleic acid
acid molecules
human papillomavirus
molecules encoding
vaccine
Prior art date
Application number
NO20051561A
Other languages
English (en)
Other versions
NO20051561D0 (no
Inventor
Gerald Wayne Gough
Christopher Michael Roberts
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20051561D0 publication Critical patent/NO20051561D0/no
Publication of NO20051561L publication Critical patent/NO20051561L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter og preparater egnet ved behandling og forebygging av infeksjoner med humant papillomavims. Spesielt angår oppfinnelsen nukleinsyremolekyler som koder for El og/eller E2 og vektorer egnet for DNA-vaksineavgivelse, og farmasøytiske preparater inneholdende dem. Fremgangsmåter for fremstilling av disse molekyler, vektorer og preparater er også påtenkt.
NO20051561A 2002-10-03 2005-03-23 Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. NO20051561L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222953.2A GB0222953D0 (en) 2002-10-03 2002-10-03 Novel Compounds
PCT/EP2003/011158 WO2004031222A2 (en) 2002-10-03 2003-10-01 Dna vaccine encoding at least two nonstructural early proteins of papillomavirus

Publications (2)

Publication Number Publication Date
NO20051561D0 NO20051561D0 (no) 2005-03-23
NO20051561L true NO20051561L (no) 2005-06-02

Family

ID=9945247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051561A NO20051561L (no) 2002-10-03 2005-03-23 Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.

Country Status (21)

Country Link
US (2) US20060165713A1 (no)
EP (1) EP1546191A2 (no)
JP (1) JP2006516386A (no)
KR (1) KR20050050115A (no)
CN (1) CN100393878C (no)
AR (1) AR041515A1 (no)
AU (1) AU2003294672A1 (no)
BR (1) BR0314986A (no)
CA (1) CA2500093A1 (no)
CO (1) CO5580837A2 (no)
GB (1) GB0222953D0 (no)
IS (1) IS7775A (no)
MA (1) MA27474A1 (no)
MX (1) MXPA05003558A (no)
NO (1) NO20051561L (no)
NZ (1) NZ539154A (no)
PL (1) PL376534A1 (no)
RU (1) RU2354701C2 (no)
TW (1) TW200411055A (no)
WO (1) WO2004031222A2 (no)
ZA (1) ZA200503201B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
US8420103B2 (en) * 2007-01-30 2013-04-16 Transgene S.A. Papillomavirus vaccines
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
AU2011268934B2 (en) 2010-06-25 2015-09-10 Nykode Therapeutics ASA Homodimeric protein constructs
EP3209676A4 (en) * 2014-10-24 2018-03-28 Hpvvax, Llc Cancer and skin lesion treatment
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
CA3023022A1 (en) * 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CN117203342A (zh) * 2020-11-25 2023-12-08 普雷西根公司 人乳头瘤病毒疫苗及其用于hpv相关疾病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
DE60124918T2 (de) * 2000-07-21 2007-08-02 Glaxo Group Ltd., Greenford Kodon-optimierte papillomavirussequenzen

Also Published As

Publication number Publication date
NZ539154A (en) 2007-05-31
IS7775A (is) 2005-03-29
KR20050050115A (ko) 2005-05-27
TW200411055A (en) 2004-07-01
BR0314986A (pt) 2005-08-09
AU2003294672A1 (en) 2004-04-23
CA2500093A1 (en) 2004-04-15
EP1546191A2 (en) 2005-06-29
CO5580837A2 (es) 2005-11-30
US20060165713A1 (en) 2006-07-27
RU2005109155A (ru) 2006-03-10
US20070264283A1 (en) 2007-11-15
JP2006516386A (ja) 2006-07-06
MXPA05003558A (es) 2005-06-03
RU2354701C2 (ru) 2009-05-10
NO20051561D0 (no) 2005-03-23
CN1720261A (zh) 2006-01-11
WO2004031222A3 (en) 2004-08-19
ZA200503201B (en) 2006-06-28
CN100393878C (zh) 2008-06-11
MA27474A1 (fr) 2005-08-01
AR041515A1 (es) 2005-05-18
GB0222953D0 (en) 2002-11-13
PL376534A1 (pl) 2006-01-09
WO2004031222A2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NZ543467A (en) The severe acute respiratory syndrome coronavirus
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
HUP0401534A2 (hu) Módosított humán IX. faktor
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
NO20055624L (no) Tropanderivater og deres anvendelse som Ace-inhibitorer
WO2009037183A3 (de) Nukleinsäurehaltige kosmetische und/oder pharmazeutische zubereitung zur induktion antimikrobieller peptide in epithelialen deckgeweben
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
CL2009000791A1 (es) Compuestos derivados de labirintopeptina; procedimiento para prepararlos que comprende fermentar la cepa actinomadura namibiensis (dsm 6313); uso de los compuestos para tratar infecciones bacterianas, infecciones viricas y/o dolor; composicion farmaceutica que los comprenden; dna que codifica la preprolabirintopeptina a2.
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE60334008D1 (de) Reduzierter slam abhängiger zell eintritt

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application